Clinical trialNCT05607108RecruitingPhase 2Interventional

A Study of ZEN003694 in People With Squamous Cell Lung Cancer

SponsorMemorial Sloan Kettering Cancer CenterEnrollment13Squamous Cell Lung Cancer

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The purpose of this study is to find out whether ZEN003694 is an effective treatment for people with advanced squamous cell lung cancer with a mutation in the NSD3 gene. ZEN003694 is a type of drug called a BET inhibitor. Researchers think ZEN003694 may help here because the drug works by blocking a group of proteins called bromodomain and extra-terminal (BET) proteins, which may counteract the effect of NSD3 on tumor growth. Blocking these proteins may slow or stop the growth of the cancer.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Paul Paik, MD
Memorial Sloan Kettering Cancer Center
Principal InvestigatorKOL profile →
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

7 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Memorial Sloan Kettering at Basking Ridge Limited Protocol Activities
Basking Ridge, New Jersey, United States
Recruiting
Memorial Sloan Kettering Monmouth (all Protocol Activities)
Middletown, New Jersey, United States
Recruiting
Memorial Sloan Kettering Bergen (all Protocol Activities)
Montvale, New Jersey, United States
Recruiting
Memorial Sloan Kettering Suffolk-Commack (all Protocol Activities )
Commack, New York, United States
Recruiting
Memorial Sloan Kettering Westchester (all Protocol Activities)
Harrison, New York, United States
Recruiting
Memorial Sloan Kettering Cancer Center (all Protocol Activities)
New York, New York, United States
Recruiting
Memorial Sloan Kettering Nassau (all Protocol Activities)
Uniondale, New York, United States
Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

ZEN003694

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 1 Nov 2022
Primary completion: 30 Nov 2027
Completion: 30 Nov 2027
Last update posted: 11 Mar 2026
Registered enrollment: 13
Registry id: NCT05607108

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.